Elecsys® Total -Tau CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of total Tau in human Cerebrospinal Fluid (CSF)

Elecsys® Total -Tau CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of total Tau in human Cerebrospinal Fluid (CSF)

Tau (tubulin-associated unit) protein is one of the two hallmarks of Alzheimer’s disease, besides β-Amyloid (1-42)(Abeta42). The Elecsys Total-Tau CSF assay is designed to detect the six human brain Tau isoforms or fragments in human CSF.

Many studies show that total Tau CSF (tTau) levels increase around 2 – 3 fold in mild moderate Alzheimer’s Disease patients compared to age matched controls while CSF β Amyloid (1 42) levels decrease to around half the level in controls.1,2 CSF tTau has been shown to reflect the intensity of the neuronal and axonal damage and degeneration. High CSF tTau is also associated with a faster progression from Mild Cognitive Impairment (MCI) to AD.3

 

Platform availability

MODULAR ANALYTICS E170, cobas e 601, cobas e 602, cobas e 411

Elecsys® Total -Tau CSF

Elecsys® Total -Tau CSF

  • Systems

    cobas e 411 analyzer, cobas e 601 / cobas e 602 modules, MODULAR ANALYTICS E170

  • Testing Time

    18 minutes

  • Test principle

    Sandwich principle

  • Calibration

    2-point

  • Traceability

    LC-MS/MSTau (172-205) [pThr181]amidTau (156-166) – Tau (192-202) – Tau (217-227) amid

  • Sample material

    Human Cerebrospinal Fluid (CSF)

  • Sample volume

    50 μL

  • LoB (Limit of Blank)

    30 pg/mL

  • LoD (Limit of Detection)

    60 pg/mL

  • LoQ (Limit of Quantitation)

    80 pg/mL

  • Measuring range

    8-1,300 pg/mL (defined by the Limit of Quantitation and the maximum of the master curve)

    Values below the Limit of Quantitation are reported as < 80 pg/mL

    Values above the measuring range are reported as > 1,300 pg/mL

  • Intermediate precision

    cobas e 411: 2.2-3.5% (4.14 - 40.3 pg/mL)
    E170, cobas e 601, cobas e 602: 1.4% -2.1% (1.63 – 19.5 pg/mL)

References

 

  1. Mattsson, N., Zetterberg, H., Hansson, O. et.al. (2009). JAMA 22, 302(4), 385-93.
  2. Hampel, H., Blennow, K. (2004). Dialogues Clin Neurosci, 6(4), 379-390. 
  3. Blom, ES., Giedraitis, V., Zetterberg, H. et al. (2009). Dement Geriatr Cogn Disord, 27(5), 458-64.